Navigation Links
Jennerex Appoints Gregory W. Schafer as Chief Financial Officer
Date:6/22/2010

ultant for Deloitte and Touche, LLP and as an engineer specializing in biologics manufacturing.  Mr. Schafer also serves on the board of directors for Nile Therapeutics, a public biotechnology company.  He received his MBA from the Anderson Graduate School of Management at the University of California, Los Angeles and a BSE in mechanical engineering from the University of Pennsylvania.

About Jennerex

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer.  The Company's lead product JX-594 is currently in two mid-stage clinical trials in patients with primary liver cancer — an international, randomized, Phase 2 dose-response clinical trial, and a Phase 2 study in combination with sorafenib.  Prior, published studies designed to establish dose levels and the safety profile of JX-594 have shown its ability to selectively target a variety of common cancer tumor types.  JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through viral replication, the reduction of the blood supply to tumors through vascular targeting and destruction and the stimulation of the body's immune response against cancer cells.  Jennerex is headquartered in San Francisco and has research and development operations in Ottawa, Canada and Busan, South Korea.  For more information about Jennerex, please visit

SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Jennerex Announces Presentations at Upcoming Conferences
2. Jennerex, Inc. Receives EMEA Orphan Drug Designation for JX-594 for the Treatment of Hepatocellular Carcinoma
3. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
4. Jennerex Treats First Patients in Phase 2 JX-594 Trial for Liver Cancer
5. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus
6. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
7. Jennerex Publishes Promising Results from Cancer Clinical Trial of JX-594 in Lancet Oncology
8. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
9. EPEMED, the European Personalised Medicine Association, Appoints Executive Director
10. Amylin Pharmaceuticals Appoints Christian Weyer, MD Senior Vice President, Research and Development
11. Renhuang Appoints PricewaterhouseCoopers to Develop a SOX 404 Compliance Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... JUPITER, Fla. , Aug. 3, 2015 /PRNewswire/ ... announced initiation of its second clinical development program ... drug candidate, CL-H1T.  CL-H1T contains ... is being developed as a treatment for migraine ... "Many patients with migraine headaches ...
(Date:8/3/2015)... and FLORHAM PARK, N.J. , ... once-daily naldemedine met its primary and secondary endpoints in ... of opioid-induced constipation (OIC) in adult patients with chronic ... mu-opioid receptor antagonist (PAMORA). This is the third Phase ... key secondary endpoints. Study results showed that ...
(Date:8/3/2015)... ZIONA, Israel , August 3, 2015 /PRNewswire/ ... today announced it received the statistical analysis of results from ... administered in the BVX-005 phase II trial which took place ... which did not exist at the time of the study- ... that caused the epidemic in the United States ...
Breaking Medicine Technology:Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3
(Date:8/3/2015)... ... August 03, 2015 , ... ... 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb B2B Awards ... brands. BESLER Consulting's campaign for the launch of their Readmissions Analytics product was ...
(Date:8/3/2015)... ... 03, 2015 , ... To date, many pharmaceutical and biotech ... of benefits, allowing them to gain access to capabilities that cannot be found ... resources, get access to innovation and ensure timely introduction of product into the ...
(Date:8/3/2015)... ... August 03, 2015 , ... A recent survey by ... of Hispanics believe people can positively affect their diabetes, few look beyond diet ... making diet changes was important. Far fewer participants mentioned the need for exercise ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... and the largest online retailer of nutritional supplements, has officially opened the ... for 11 awards in the following categories:, ,     Brand ...
(Date:8/3/2015)... Venice Beach, CA (PRWEB) , ... August 03, ... ... supporting individuals suffering from ALS and amputation , AUGUST 3, 2015 – Since ... DIY category in March 2015, Not Impossible – an organization whose mission is ...
Breaking Medicine News(10 mins):Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 2Health News:Global CRO Market Space Reviewed by Aniruddha Sowale in In-demand Research Report Available at MarketPublishers.com 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 2Health News:BPI Sports is Nominated for 11 Different 2015 Bodybuilding.com Supplement Awards 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4
... Kentucky Ranks 47th Nationwide in Health Status; Anthem Blue ... services to more than 5,000, Kentuckians located in ... LOUISVILLE, Ky., Nov. 14 Anthem Blue Cross and ... program that,incorporates public health data to identify and help ...
... in with a strong,70% Omega-3 fatty acid content, ... formula, is now available in convenient,smaller-sized soft gels. ... same exceptionally high concentrated oil as Ultimate Omega, ... swallowing. Ideal for ages 5,through adult, the all ...
... FORT MYERS, Fla., Nov. 14 NeoGenomics, Inc.,(OTC Bulletin ... its results for the third quarter of FY 2007.,Significant ... nine,months of the year included the following: Third ... revenues in Q3 07 vs. Q3 06 -- ...
... Ill., Nov. 14 Delta Dental, the nation,s,largest ... Readers,Choice Award from Benefits Selling magazine as the ... and network availability. The,awards were announced in the ... Selling surveys its readers annually, asking them to ...
... reporting the first successful strategy to reduce smokers nicotine ... study provides strong support for proposals now being considered ... according to the research team. , The key to ... of gradually decreasing nicotine content over a number of ...
... 14 On the first United Nations World,Diabetes ... to develop national policies for the prevention, care ... to consider the need,for a diabetes global fund ... at the World Diabetes Day press conference, Dr ...
Cached Medicine News:Health News:Anthem Blue Cross and Blue Shield in Kentucky Announces Release of State Health Index 2Health News:Anthem Blue Cross and Blue Shield in Kentucky Announces Release of State Health Index 3Health News:Anthem Blue Cross and Blue Shield in Kentucky Announces Release of State Health Index 4Health News:Nordic Naturals Introduces Ultimate Omega 500 - Their Best Selling Formula Now Available in a Smaller Size Soft Gel! 2Health News:NeoGenomics Announces Results for the 3rd Quarter 2007 2Health News:NeoGenomics Announces Results for the 3rd Quarter 2007 3Health News:NeoGenomics Announces Results for the 3rd Quarter 2007 4Health News:NeoGenomics Announces Results for the 3rd Quarter 2007 5Health News:NeoGenomics Announces Results for the 3rd Quarter 2007 6Health News:NeoGenomics Announces Results for the 3rd Quarter 2007 7Health News:NeoGenomics Announces Results for the 3rd Quarter 2007 8Health News:Brokers Name Delta Dental the Best in Coverage, Plan Design and Networks 2Health News:Nicotine addiction slashed in test of new cigarette smoking strategy 2Health News:Nicotine addiction slashed in test of new cigarette smoking strategy 3Health News:First United Nations World Diabetes Day Unites Global Diabetes Community to Fight the Epidemic 2Health News:First United Nations World Diabetes Day Unites Global Diabetes Community to Fight the Epidemic 3Health News:First United Nations World Diabetes Day Unites Global Diabetes Community to Fight the Epidemic 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: